Zhenyi Medical Honored on Timedia's 'Most Promising Investment Value List' Amid IPO Filing

Jiangsu Trulive Medtech Co., Ltd. is a leading cardiovascular intervention platform company in China. The company focuses on cardiovascular disease areas with extremely high mortality and disability rates, where domestically produced products are still lacking. Its business comprehensively covers four major disease areas: heart valves, heart failure, peripheral, and coronary diseases, making it the first domestic platform-based high-end medical device company to fully layout these four key fields with substantial progress achieved in core products. With strong research and development capabilities and an experienced, complete operational team, Trulive Medtech has developed high-quality, proprietary medical devices and comprehensive solutions with independent intellectual property rights, filling the gap in China’s high-end vascular intervention medical device market. It provides more advanced and diverse treatment options for Chinese doctors and patients, offering "Chinese solutions" and contributing "Chinese wisdom" in many细分 markets within the cardiovascular intervention field that have long been monopolized by imported products.